Tandem Diabetes Care (TNDM) Equity Income (2024 - 2026)

Tandem Diabetes Care has reported Equity Income for 3 years, with the latest figure at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Income fell 11.43% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$14.5 million (down 161.62% YoY), and the FY2025 full-year result was -$14.2 million, down 591.38% from the prior year.
• Equity Income for Q1 2026 stood at -$3.9 million, up from -$4.6 million in the prior quarter.
• The five-year high for Equity Income was -$2.1 million in Q4 2024, with the low at -$4.6 million in Q4 2025.
• Historically, Equity Income has averaged -$3.3 million across 3 years, with a median of -$3.4 million in 2025.
• Annual changes were most pronounced in 2025 — Equity Income slumped 121.77% — and 2026, when it fell 11.43%.
• Tandem Diabetes Care's Equity Income stood at -$2.1 million in 2024, then tumbled by 121.77% to -$4.6 million in 2025, then increased by 14.34% to -$3.9 million in 2026.
• The last three Equity Income figures came in at -$3.9 million (Q1 2026), -$4.6 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.